← All trials
NCT04542330
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2020
- Primary completion
- Jan 31, 2022
- Completion date
- Mar 31, 2022
- First posted
- Sep 9, 2020
- Last posted
- Nov 24, 2020
- Enrollment
- 1900
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bandim Health ProjectLead sponsor
- University of Southern DenmarkCollaborator
- University of Southern DenmarkCollaborator
- University of Southern DenmarkOverall official - principal investigator
- University of Southern DenmarkStudy chair
- Government of DenmarkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.